Close mobile menu×
Close mobile menu

Dawn L. Hershman, MD, MS

Board Certifications: 
Medical Oncology, Internal Medicine
Expertise in: 
Cancer Care, Breast Cancer
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Medical Oncology
  • Internal Medicine

Clinical Expertise

  • Cancer Care
  • Breast Cancer
  • Breast Oncology
  • Medical Oncology

Specialties

Education & Training

  • Albert Einstein College of Medicine - Yeshiva University
  • Internship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Honors & Awards

  • Alpha Omega Alpha, Albert Einstein College of Medicine. 
  • Janet M. Glasgow Achievement Award
  • Ewig Award for Teaching Excellence
  • AVON Foundation Breast Cancer Medical Advancement Award
  • ASCO Leadership Development Program
  • ASCO Research Professorship in Comparative Effectiveness Research in Breast Cancer
  • Americal Association of Clinical Investigators

About Dawn Hershman

The Breast Cancer Program is committed to delivering a comprehensive and seamless continuum of breast care.

Dr. Hershman is Leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University. She completed her medical degree at the Albert Einstein College of Medicine, and completed her internal medicine and oncology fellowship training at Columbia University Medical Center, where she served as Chief Resident. During that time she completed a Master's degree in Biostatistics at the Mailman School of Public Health. She has developed nationally recognized expertise in breast cancer treatment, prevention, and survivorship.

She has also developed a comprehensive multidisciplinary program to study ways of improving cancer care delivery (CCD), reducing disparities and designing studies to improve the quality of life and quality of care in BC survivors. She has received funding from the American Society of Clinical Oncology, American Cancer Society, Department of Defense, Breast Cancer Research Foundation, PCORI, and the National Cancer Institute. She currently has several R01 grants, and has mentored numerous faculty members who have been granted mentored career development awards. Dr. Hershman has published over 250 scientific articles and has received several awards including the highly prestigious Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology and the Advanced Medical Achievement Award from the Avon Foundation.

She has several national leadership roles in oncology. Within SWOG she is the Co-Pi of the NCORP Research Base and is Co-Chair of the Cancer Care Delivery Committee. Within ASCO she was selected to participate in the first Leadership Development Program and has been the Chair of the Grants Selection Committee, the leader of the education tack for Health Services, she has been on numerous committees including the quality of care committee, the obesity task force and the workforce advisory committee. She is on the editorial board for the Journal of Clinical Oncology and is an Associate Editor at the Journal of the National Cancer Institute.

Academic Titles

  • Professor of Medicine and Epidemiology

Administrative Positions

  • Professor of Medicine and Epidemiology
  • Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center

Committee/Societies/Council Memberships

ASCO

ASCI

SWOG

AACR

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Languages

  • Spanish

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Indemnity
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Indemnity
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO
  • The Empire Plan (NYSHIP)

VNSNY CHOICE

  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone: (212) 305-5098
Fax:
(212) 305-6798
Primary

Research

Clinical trials in breast cancer treatment and prevention, supportive care, quality of care and cancer survivorship

Research Interests

  • Clinical trials in breast cancer treatment and prevention
  • Supportive care and cancer survivorship

Grants

National Cancer Institute

American Cancer Society

Breast Cancer Research Foundation

Susan Komen Foundation

Avon Foundation

National Center for Complementary and Alternative Medicine

Patient Centered Outcomes Research Institute

BONE AND BREAST CANCER MOLECULAR INTERACTIONS (Federal Gov)

Dec 1 2015 - Nov 30 2020

REDUCING OVERUSE AND INCREASING UNDERUSE TO IMPROVE THE QUALITY AND SAFETY OF BREAST CANCER CARE (Private)

Jul 1 2015 - Jun 30 2020

COMORBIDITY, TOXICITY AND BREAST CANCER SURVIVAL AMONG WOMEN ON AND OFF CLINICAL TRIALS (Private)

Aug 2 2016 - Aug 1 2019

SWOG NCORP RESEARCH BASE (Federal Gov)

Aug 1 2014 - Jul 31 2019

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 1 2014 - Jun 30 2019

SWOG NETWORK GROUP OPERATIONS CENTER OF THE NCTN (Federal Gov)

Mar 1 2016 - Feb 28 2019

USING SWOG-MEDICARE DATABASE TO EVALUATE LONG-TERM TOXICITIES OF CANCER SURVIVORS (Federal Gov)

Feb 15 2013 - Jan 31 2018

BREAST CANCER ACCESS TO CARE AND DISPARITIES RESEARCH PROGRAM (Private)

Jan 1 2017 - Dec 31 2017

THE INFLUENCE OF HOSPITAL VARIABILITY ON THE MANAGEMENT OF CANCER-ASSOCIATED COMPLICATIONS (Federal Gov)

Jan 1 2013 - Dec 31 2017

DESIGNING A PROTOTYPE OF N-OF1 TRIALS OF DEPRESSIVE SYMPTOM MANAGEMENT IN CANCER SURVIVORS (Federal Gov)

Sep 26 2015 - Sep 29 2017

ACUPUNCTURE OF ARMOTASE INHIBITOR RELATED ARTHRALGIAS IN BREAST CANCER PATIENTS (Federal Gov)

Sep 1 2011 - Jun 30 2017

BREAST CANCER ACCESS TO CARE AND DISPARITIES RESEARCH PROGRAM (Private)

Jan 1 2016 - Dec 31 2016

A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVENT THERAPY FOR PATIENTS WITH HER2-POSIT (Private)

Jan 1 2013 - Dec 31 2016

UNDERSTANDING BARRIERS TO QUALITY CANCER CARE (Private)

Oct 1 2015 - Sep 30 2016

A STRUCTURED APPROACH TO PRIORITIZING CANCER RESEARCH USING STAKEHOLDERS AND VALUE OF INFORMATION (Private)

Oct 1 2013 - Sep 30 2016

A PRAGMATIC TRIAL TO IMPROVE COLONY STIMULATING FACTOR USE IN CANCER (Private)

Jul 1 2015 - Aug 31 2016

STUDY EVALUATING SAFETY AND EFFICACY OF THE ADDITION OF VELIPARIB PLUS CARBOPLAIN VS. THE ADDITION OF CARBOPLATIN TO STANDARD NEOADJUVANT CHEMOTHERAPY VS. STANDARD NEOADJUVANT CHEMOTHERAPY IN SUBJECT (Private)

Aug 5 2015 - Aug 4 2016

ECONOMIC EVALUATION OF THE COMPARATIVE VALUE OF STEREOTACTIC BODY RADIOTHERAPY VERSUS SURGERY FOR STAGE 1 NON-SMALL CELL LUNG CANCER (Private)

Jul 1 2015 - Jun 30 2016

A RANDOMIZED TRIAL OF TOPICAL MENTHOL FOR CHEMOTHERAPY INDUCED NEUROPATHY (Federal Gov)

Jul 1 2014 - Jun 30 2016

LIFESTYLE AND MOLECULAR FACTOR OF BONE HEALTH IN BREAST CANCER SURVIVORS (Federal Gov)

Sep 4 2012 - Jun 30 2016

DESIGNING A PROTOTYPE OF N-OF1 TRIALS OF DEPRESSIVE SYMPTOM MANAGEMENT IN CANCER SURVIVORS (Federal Gov)

Sep 26 2015 - Jan 25 2016

BREAST CANCER ACCESS TO CARE AD DISPARITIES RESEARCH PROGRAM (Private)

Jan 1 2015 - Dec 31 2015

REDUCING OVERUSE, IMPROVING ADHERENCE AND UNDERSTANDING BARRIERS TO QUALITY CANCER CARE (Private)

Oct 1 2014 - Sep 30 2015

ZOL446E2352:A PROSPECTIVE RANDOMIZED DOUBLE BLIND STRATIFIEDPLACEBO CONTROLLED MULTICENTER 2 ARM TRIAL OF THE CONTINUED (P&S Industry Clinical Trial)

Sep 17 2010 - Sep 17 2015

NERATINIB HKI 272: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLTRIAL OF NERATINIB (HKI 272) AFTER TRASTUZUMAB IN WOMEN (P&S Industry Clinical Trial)

Aug 16 2010 - Aug 16 2015

ELECTRONIC EDUCATIONAL ALERT TO REDUCE OVERUSE OF GRANULOCYTE COLONY STIMULATING FACTOR IN PATIENTS HOSPITALIZED FOR FEBRILE NEUTROPENIA (Private)

Jul 1 2014 - Jun 30 2015

THE RELATIONSHIP BETWEEN INSURANCE AND CANCER-RELATED PRESCRIPTION DRUG USE (Private)

Jul 1 2012 - Jun 30 2015

RACIAL DISPARITIES IN THE INITIATION AND INTENSITY OF ADJUVANT THERAPY FOR BREAST CANCER (Federal Gov)

May 20 2005 - May 19 2015

TRASTUZUMAB OR CAPECITABINE AND LAPITINIB IN SUBJECTS WITH HER2POSITIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (P&S Industry Clinical Trial)

May 7 2010 - May 7 2015

AVON FOUNDATION BREAST CANCER PROGRAM AT THE HERBERT IRVING COMPREHENSIVE CANCER CENTER OF COLUMBIA UNIVERSITY MEDICAL CENTER AND NEW YORK-PRESBYTERIAN HOSPITAL (Private)

Jan 1 2013 - Dec 31 2014

GENOME WIDE PREDICTORS OF TREATMENT RELATED TOXICITIES (Federal Gov)

Jan 19 2011 - Dec 31 2014

COMPARISON OF PREDICTIVE RECURRENCE IN FEMALE AFREICAN AMERICAN AND CAUCASIAN PTS. WITH EARLY STAGE BREAST CANCER UTILIZ (P&S Industry Clinical Trial)

Oct 15 2009 - Oct 15 2014

SHORT AND LONG TERM CONSEQUENCES OF BREAST CANCER TREATMENT (Private)

Oct 1 2013 - Sep 30 2014

PHASE I-II TRIAL OF VORINOSTAT PLUS WEEKLY PACLITAXEL AND TRASTUZUMAB FOLLOWED BY DOXORUBICIN-CYCLOPHOSPHAMIDE IN PATIEN (P&S Industry Clinical Trial)

Sep 15 2009 - Sep 15 2014

COMPARATIVE EFFECTIVENESS OF SURGICAL TREATMENTS FOR LUNG CANCER IN THE ELDERLY (Federal Gov)

Sep 30 2010 - Jul 31 2014

SWOG TREATMENT GRANT (Federal Gov)

Jul 1 2013 - Jun 30 2014

YOUNG AND STRONG: AN EDUCATION AND SUPPORTIVE CARE INTERVENTION STUDY OFR YOUNG WOMENT WITH BREAST CANCER (Private)

Mar 6 2013 - Jun 30 2014

PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY USING OPTICAL TOMOGRAPHIC IMAGING IN WOMEN WITH BREAST CANCER (Private)

Nov 10 2011 - Nov 9 2013

SHORT AND LONG TERM CONSEQUENCES OF BREAST CANCER TREATMENT (Private)

Oct 1 2012 - Sep 30 2013

HOSPITAL AND COUNTY-LEVEL PREDICTORS OF IMMEDIATE BREAST RECONSTRUCTION POST-MASTECTOMY (Federal Gov)

Sep 30 2012 - Sep 29 2013

DETERMINANTS AND RISKS OF USE OF OVERUSE OF EXPENSIVE ONCOLO GY DRUGS (Federal Gov)

Sep 1 2008 - Jul 31 2013

RCT OF EXERCISE ON AROMATASE INHIBITOR SIDE EFFECTS IN BREAST CANCER SURVIVORS (Federal Gov)

Aug 6 2009 - May 31 2013

USING PHYSIOLOGICAL AGE TO PREDICT CHEMOTHERAPY TOXICITY (Federal Gov)

Jul 1 2007 - May 31 2013

ASTRAZENECA -- IRUSA (P&S Industry Clinical Trial)

Apr 10 2008 - Dec 31 2012

SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT (Federal Gov)

Apr 1 2008 - Dec 31 2012

STUDIES IN CANCER SURVIVORSHIP (Private)

Oct 1 2011 - Sep 30 2012

A MULTICENTER PHASE II TRAIL OF PARP INHIBITOR ABT-888 IN TRIPLE NEGATIVE BREAST CANCER SURVIVORS (Federal Gov)

Sep 30 2011 - Sep 29 2012

PHASE 1B DOSE ESCALATION STUDY OF POLYPHENON E IN WOMEN WITH A HISTORY OF HORMONE RECEPTOR-NEGATIVE BREAST CANCER (Federal Gov)

Sep 30 2006 - Sep 29 2012

PHASE 1B DOSE ESCALATION STUDY OF POLYPHENON E IN WOMEN WITH A HISTORY OF HORMONE RECEPTOR-NEGATIVE BREAST CANCER (Federal Gov)

Sep 30 2006 - Sep 29 2012

TAXANE-INDUCED NEUROPATHY IN BREAST CANCER SURVIVORS--INCIDE NCE, PREDICTORS AND TREATMENT (Private)

Jul 1 2007 - Jun 30 2012

WYETH 3144A1-203-WW (P&S Industry Clinical Trial)

Jul 25 2007 - Mar 31 2012

ZOLEDRONIC ACID FOR PREVENTION OF BONE LOSS IN PREMENOPAUSALWOMEN WITH EARLY STAGE BREAST CANCER (IRB 14069) (P&S Industry Clinical Trial)

Jan 14 2002 - Mar 31 2012

STUDIES IN CANCER SURVIVORSHIP (Private)

Oct 1 2010 - Dec 31 2011

"SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT" (Federal Gov)

Apr 1 2008 - Dec 31 2011

ADJUVANT BREAST CANCER THERAPIES:RACE, VARIATIONS IN CARE AN D SURVIVAL (Private)

Jan 1 2008 - Dec 31 2011

WYETH -- 3144A1-2204 (P&S Industry Clinical Trial)

Mar 17 2008 - Oct 31 2011

IMPROVING POST-TREATMENT CARE OF LATINA BREAST CANCER SURVIV ORS (Private)

Nov 1 2007 - Oct 31 2011

STUDY OF ORAL CCI-779 ADMINISTERED IN COMBINATION WITH LETROZOLE VERSUS LETROZOLE ALONE AS FIRST LINE HORMONAL (P&S Industry Clinical Trial)

Jun 30 2004 - Oct 6 2011

"INTERVENTION TO REDUCE CANCER TREATMENT COMPLICATIONS" (Private)

Oct 1 2009 - Sep 30 2010

Selected Publications

1. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014 Jun 20;32(18):1941-67.
2. Hershman DL, Neugut AI, Shim JJ, Glied S, Tsai WY, Wright JD. Erythropoiesis-Stimulating Agent Use After Changes in Medicare Reimbursement Policies. J Oncol Pract. 2014 Jul;10(4):264-9.
3. Mandelblatt JS, Huang K, Makgoeng SB, Luta G, Song JX, Tallarico M, Roh JM, Munneke JR, Houlston CA, McGuckin ME, Cai L, Clarke Hillyer G, Hershman DL, Neugut AI, Isaacs C, Kushi L. Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative J Oncol Pract. 2014 Aug 26.
4. Wright JD, Tergas AI, Burke WM, Cui RR, Ananth CV, Chen L, Hershman DL. Uterine Pathology in Women Undergoing Minimally Invasive Hysterectomy using Morcellation. JAMA. 2014. Sep 24;312(12):1253-5.
5. Kwan ML, Lo JC, Tang L, Laurent CA, Roh JM, Chandra M, Hahn TE, Hong CC, Sucheston-Campbell L, Hershman DL, Quesenberry CP Jr, Ambrosone CB, Kushi LH, Yao S. Bone health history in breast cancer patients on aromatase inhibitors. PLoS One. 2014 Oct 29;9(10):e111477.
6. Kalinsky K, Lim EA, Andreopoulou E, Desai AM, Jin Z, Tu Y, Hibshoosh H, Wang A, Greenlee H, Crew KD, Maurer M, Sparano JA, Hershman DL. Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. Cancer Invest. 2014 Oct;32(9):439-44.
7. Hershman DL, Lacchetti C, Loprinzi CL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2014 Nov;10(6):e421-4.
8. Reimers LL, Crew KD, Bradshaw PT, Santella RM, Steck SE, Sirosh I, Terry MB, Hershman DL, Shane E, Cremers S, Dworakowski E, Teitelbaum SL, Neugut AI, Gammon MD. Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. Cancer Causes Control. 2014 Nov 25. [Epub ahead of print]
9. Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, Fabian CJ, Gucalp A, Hershman DL, Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill JK, Wollins DS, Hudis CA. American society of clinical oncology position statement on obesity and cancer. J Clin Oncol. 2014 Nov 1;32(31):3568-74
10. Hershman DL, Tsui J, Meyer J, Glied S, Hillyer, G, Wright DW, Neugut AI. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early stage breast cancer. Journal of the National Cancer Institute 2014 Oct 27; 106(11).
11. Wright JD, Kostolias A, Ananth CV, Burke WM, Tergas AI, Prendergast E, Ramsey SD, Neugut AI, Hershman DL. Comparative effectiveness of robotically assisted compared with laparoscopic adnexal surgery for benign gynecologic disease. Obstet Gynecol. 2014 Nov;124(5):886-96.
12. Irwin ML, Cartmel B, Gross C, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman DL, Ligibel J. Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors. J Clin Oncol. 2014 Dec 1.
13. Unger JM;  Hershman DL; Martin D;  Etzioni R; Barlow WE;  LeBlanc M; Ramsey, SR. The Diffusion of Docetaxel in Patients with Metastatic Prostate Cancer. Journal of the National Cancer Institute 014 Dec 24;107(2).
14. Dessources K, Hou JY, Tergas AI, Burke WM, Ananth CV, Prendergast E, Chen L, Neugut AI, Hershman DL, Wright JD. Factors Associated With 30-Day Hospital Readmission After Hysterectomy. Obstet Gynecol. 2015 Jan 7. [Epub ahead of print]
15. Patankar SS, Tergas AI, Deutsch I, Burke WM, Hou JY, Ananth CV, Huang Y, Neugut AI, Hershman DL, Wright JD. High versus low-dose rate brachytherapy for cervical cancer. Gynecol Oncol. 2015 Jan 6.
16. Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Lim E, Tsai WY, Crew K, Maurer M, Kalinsky K, Hershman DL. ¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. J Acad Nutr Diet. 2015 Jan 5.
17. Wright, JD, Tergas, AI, Ananth, CV, Burke, WM, Chen, L, Neugut, AI, Richards, CA, Hershman, DL. Relationship Between Surgical Oncologic Outcomes and Publically Reported Hospital Quality and Satisfaction Measures. Journal of the National Cancer Institute 2015 Jan 24;107(3).
18. Hershman DL, Tsui J, Wright DW, Coromilis, E, Neugut AI. Household net worth, racial disparities and hormonal therapy adherence among women with early stage breast cancer. J. Clin. Oncol. 2015 Mar 20;33(9):1053-9
19. Accordino M, Wright JD, Buono D, Neugut AI, Hershman DL. Trends in Use and Safety of Image-Guided Transthoracic Needle Biopsies in Cancer Patients. J Oncol Pract. 2015 Jan 20.
20. Wright, JD, Tergas, AI, Ananth, CV, Burke, WM, Chen, L, Neugut, AI, Hershman, DL. Utilization and Prevalence of Underlying Pathology in Women Who Undergo Electric Power Morcellation for Myomectomy. JAMA Oncology. February 19, 2015
21. Dinkelspiel HE, Tergas AI, Zimmerman LA, Burke WM, Hou JY, Chen L, Hillyer G, Neugut AI, Hershman DL, Wright JD. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. Gynecol Oncol. 2015 Feb 20
22. Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst. 2015 Mar 4;107(3).
23. Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, Mumber M, Perlmutter J, Seely D, Sen A, Zick SM, Tripathy D; Society for Integrative Oncology Guidelines Working Group. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58.
24. Coromilis E, Wright JD, Huang Y, Feldman S, Neugut AI, Chen L, Hershman DL; The influence of shospital and surgeon factors on the prevalence ofaxillary evaluation in ductal carcinoma in situ. JAMA Oncology. April 9, 2015.
25. Hershman DL, Unger JM, Crew KD, Awad D, Dakhil S, Gralow J, Greenlee H, Lew DL, Minasian L, Till C, Wade JL, Meyskens F, Moinpour C. Randomized Multicenter Placebo-Controlled Trial of Omega-3-Fatty Acids for the control of Aromatase Inhibitor-Induced Musculoskeletal Pain (S0927). J. Clin. Oncol. 2015